Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 4/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.40 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | INSR | P06213 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | LYN | P07948 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30054489 | 1.00 | SCN9A (0.42) | SCN9AKIF11AKT1PKMALDH1A1 | |
| SCHEMBL16752831 | 0.87 | SCN9A (0.51) | SCN9AKIF11AKT1PKMALDH1A1 | |
| SCHEMBL13106172 | 0.81 | ADORA2A (0.53) | KIF11PKMALDH1A1CCR2KCNH2 | |
| SCHEMBL14737962 | 0.80 | KIF11 (0.41) | SCN9AKIF11PKMALDH1A1CCR2 | |
| Ammonia Solution, Strong SCHEMBL28811085 | 0.80 | ADORA2A (0.52) | KIF11PKMALDH1A1CCR2KCNH2 | |
| SCHEMBL5583119 | 0.80 | CCR2 (0.39) | KIF11PKMCCR2KCNH2MAT2A | |
| SCHEMBL18538052 | 0.79 | MAPT (0.41) | KIF11PKMALDH1A1CCR2KCNH2 | |
| SCHEMBL9179915 | 0.77 | SCN9A (0.41) | SCN9AALDH1A1GSK3BKDM4ESLC2A1 | |
| SCHEMBL3655093 | 0.77 | PRKCI (0.41) | SCN9AALDH1A1CSNK1A1GSK3BTAOK1 | |
| SCHEMBL2661304 | 0.76 | ICMT (0.36) | SCN9AKIF11AKT1PKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115551848-A | Heterocyclic compounds for controlling invertebrate pests | 巴斯夫欧洲公司 | 2022-12-30 | — | — | CN | disclosed |
| US-10336727-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180305336-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-10-25 | — | — | US | disclosed |
| US-10040779-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| EP-2934145-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170174656-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-06-22 | — | — | US | disclosed |
| US-9617242-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| CN-106414440-A | Aryl and heteroaryl substituted imidazo [1,2-a ] pyridine-3-carboxamides and their use | 拜耳制药股份公司 | 2017-02-15 | — | — | CN | disclosed |
| US-20160362408-A1 | ARYL- AND HETARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-15 | — | — | US | disclosed |
| EP-3077394-A1 | ARYL- AND HETARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2016-10-12 | — | — | EP | disclosed |
| US-20070244169-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-10-18 | — | — | US | disclosed |
| US-20070244169-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-10-18 | — | — | US | disclosed |
| WO-2007075847-A2 | GLUCOKINASE ACTIVATORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007075847-A2 | GLUCOKINASE ACTIVATORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-05 | — | — | WO | disclosed |
| EP-1483241-A4 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2006-12-13 | — | — | EP | disclosed |
| US-7087604-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060135503-A1 | Cyclic derivatives as modulators of chemokine receptors activity | CHERNEY ROBERT J | 2006-06-22 | — | — | US | disclosed |
| EP-1483241-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20030216434-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-20 | — | — | US | disclosed |
| WO-2003075853-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305336-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM5C | SCN9A 3558/4885KIF11 4326/4885AKT1 2511/4885 |
| US-10040779-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM5C | SCN9A 3558/4885KIF11 4326/4885AKT1 2511/4885 |
| US-20170174656-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM5C | SCN9A 3558/4885KIF11 4326/4885AKT1 2511/4885 |
| US-20160362408-A1 | ARYL- AND HETARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDES AND USE THEREOF | AADAC, PAH, CYP2C8 | SCN9A 4187/4885KIF11 4880/4885AKT1 3519/4885 |
| US-20070244169-A1 | GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | SCN9A 3230/4885KIF11 3005/4885AKT1 1091/4885 |
| US-20060135503-A1 | Cyclic derivatives as modulators of chemokine receptors activity | CCL11, CCR1, CCL2 | SCN9A 2562/4885KIF11 3391/4885AKT1 873/4885 |
| US-10336727-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM5C | SCN9A 3558/4885KIF11 4326/4885AKT1 2511/4885 |
| US-20030216434-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCR1, CCL11, CXCR1 | SCN9A 2238/4885KIF11 3349/4885AKT1 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.